AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8015504 — intervention group
Group type: EXPERIMENTAL
Intervention: dl-norgestrel alone (0.075 mg/day) for two cycles
Number of subjects: 26
Study 2597712 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Stepped-Care treatment program (systolic feedback)
Number of subjects: 15
Study 2597712 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Stepped-Care treatment program (relaxation)
Number of subjects: 15
Study 53554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 0.8 g/day
Number of subjects: 6
Study 53554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1.6 g/day
Number of subjects: 6
Study 53554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6252915 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 6
Study 30932564 — intervention group
Group type: EXPERIMENTAL
Intervention: Fault-tolerant gates implemented in the code space using the [4,2,2] code
Number of subjects: 0
Study 30932564 — intervention group
Group type: COMPARATOR
Intervention: Physically equivalent gates implemented on physical qubits
Number of subjects: 0
Study 29345724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (12-week program, twice a week for 45 minutes)
Number of subjects: 147
Study 29345724 — intervention group
Group type: COMPARATOR
Intervention: Control group (day care as usual)
Number of subjects: 147
Study 27698953 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (1.14 g/day)
Number of subjects: 16
Study 27698953 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week training
Number of subjects: 16
Study 27698953 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week training with DHA supplementation
Number of subjects: 16
Study 27698953 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 16
Study 24121690 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 713
Study 24121690 — intervention group
Group type: COMPARATOR
Intervention: HRT
Number of subjects: 713
Study 24121690 — intervention group
Group type: COMPARATOR
Intervention: Natural Cycle
Number of subjects: 713
Study 22649264 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic load meal
Number of subjects: 40
Study 22649264 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic load meal
Number of subjects: 40
Study 19212881 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptotic confidence interval approaches for the difference of proportions
Number of subjects: 0
Study 19212881 — intervention group
Group type: EXPERIMENTAL
Intervention: Method adding two successes and two failures
Number of subjects: 0
Study 19212881 — intervention group
Group type: EXPERIMENTAL
Intervention: Two examples illustrating the usage of the proposed methods
Number of subjects: 0
Study 17140647 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone monotherapy
Number of subjects: 285
Study 17140647 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT combination
Number of subjects: 285
Study 17140647 — intervention group
Group type: COMPARATOR
Intervention: Montelukast
Number of subjects: 285
Study 14557438 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol (1 mg every 12 h)
Number of subjects: 9
Study 14557438 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (200 micro g/d)
Number of subjects: 9
Study 14557438 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 micro g/d)
Number of subjects: 9
Study 11145491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 1510
Study 11145491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1510
Study 8984849 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 8 mg
Number of subjects: 99
Study 8984849 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 10 mg
Number of subjects: 99
Study 8984849 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (various doses)
Number of subjects: 99
Study 1311964 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg oral dose of dl-fenfluramine
Number of subjects: 0
Study 1311964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2992724 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-drug combination (vincristine, doxorubicin, cisplatin, etoposide, cyclophosphamide)
Number of subjects: 56
Study 31831079 — intervention group
Group type: EXPERIMENTAL
Intervention: FKB327
Number of subjects: 730
Study 31831079 — intervention group
Group type: COMPARATOR
Intervention: RP
Number of subjects: 730
Study 31831079 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 730
Study 28923138 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained group (exposed to a provocative rotating virtual scene)
Number of subjects: 0
Study 28923138 — intervention group
Group type: COMPARATOR
Intervention: Untrained group (control group)
Number of subjects: 0
Study 25588320 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam microdose (0.001 mg)
Number of subjects: 16
Study 25588320 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam regular dose (1 mg)
Number of subjects: 16
Study 25588320 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam microdose (0.003 mg)
Number of subjects: 16
Study 25588320 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam regular dose (3 mg)
Number of subjects: 16
Study 23551803 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin nasal spray 200 IU
Number of subjects: 46
Study 23551803 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) spray
Number of subjects: 46
Study 22108481 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol® supplementation for 8 weeks
Number of subjects: 53
Study 22108481 — intervention group
Group type: COMPARATOR
Intervention: Control group (equivalent students)
Number of subjects: 53
Study 19738321 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA 100 mg daily for 5 weeks
Number of subjects: 10
Study 19738321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 17218915 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with arteriovenous sheathotomy
Number of subjects: 36
Study 17218915 — intervention group
Group type: COMPARATOR
Intervention: Vitrectomy without arteriovenous sheathotomy
Number of subjects: 36
Study 17218915 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without sheathotomy)
Number of subjects: 36
Study 15111763 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 60
Study 15111763 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 60
Study 15111763 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen after progression on anastrozole
Number of subjects: 60
Study 15111763 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole after progression on tamoxifen
Number of subjects: 60
Study 15111763 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole-tamoxifen sequence
Number of subjects: 60
Study 15111763 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen-anastrozole sequence
Number of subjects: 60
Study 15111763 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen followed by anastrozole
Number of subjects: 60
Study 11230723 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO treatment for ICU anemia
Number of subjects: 184
Study 11230723 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for iron, B12, and folate deficiency
Number of subjects: 184
Study 11230723 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron studies
Number of subjects: 184
Study 9204224 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered food frequency questionnaire (FFQ)
Number of subjects: 95
Study 8271800 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples relapse prevention (RP) sessions
Number of subjects: 59
Study 8271800 — intervention group
Group type: COMPARATOR
Intervention: Behavioral marital therapy (BMT) alone
Number of subjects: 59
Study 3440931 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrup
Number of subjects: 20
Study 3440931 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet
Number of subjects: 20
Study 3440931 — intervention group
Group type: COMPARATOR
Intervention: Solution
Number of subjects: 20
Study 31908219 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine TAP block plus ERP
Number of subjects: 137
Study 31908219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 31908219 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine TAP block
Number of subjects: 137
Study 27755655 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Pillars Practice Transformation Program
Number of subjects: 18107
Study 27755655 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18107
Study 24855193 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 308
Study 24855193 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 308
Study 23288553 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (alpha-lipoic acid, vitamin C, and vitamin E)
Number of subjects: 9
Study 23288553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 21275549 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (35 mg/week)
Number of subjects: 40
Study 21275549 — intervention group
Group type: COMPARATOR
Intervention: Control (Vitamin D, alfacalcidol 1 μg/day)
Number of subjects: 40
Study 19074924 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration in patients with anterior acute myocardial infarction (AMI) with normal conduction
Number of subjects: 12546
Study 19074924 — intervention group
Group type: EXPERIMENTAL
Intervention: QRS duration in patients with anterior AMI with RBBB
Number of subjects: 12546
Study 19074924 — intervention group
Group type: COMPARATOR
Intervention: QRS duration in patients with inferior AMI with normal conduction
Number of subjects: 12546
Study 19074924 — intervention group
Group type: COMPARATOR
Intervention: QRS duration in patients with inferior AMI with RBBB
Number of subjects: 12546
Study 19074924 — intervention group
Group type: EXPERIMENTAL
Intervention: Increment of 20 ms increase in QRS duration for anterior AMI
Number of subjects: 12546
Study 19074924 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in QRS duration over 60 min after fibrinolytic therapy
Number of subjects: 12546
Study 17276969 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg daily for 12 weeks
Number of subjects: 60
Study 17276969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14975462 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose tenecteplase (0.27 microg/kg) plus high-dose eptifibatide (2 boluses of 180 microg/kg separated by 10 min, 2.0 microg/kg/min infusion)
Number of subjects: 140
Study 14975462 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-dose tenecteplase plus high-dose eptifibatide
Number of subjects: 140
Study 11532409 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI experience discussing pregnancy loss
Number of subjects: 38
Study 11532409 — intervention group
Group type: COMPARATOR
Intervention: No SPI experience
Number of subjects: 38
Study 11532409 — intervention group
Group type: EXPERIMENTAL
Intervention: SPI experience discussing rectal cancer
Number of subjects: 38
Study 9541083 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined operant programme plus cognitive/relaxation programme
Number of subjects: 148
Study 9541083 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant programme plus attention-control
Number of subjects: 148
Study 9541083 — intervention group
Group type: EXPERIMENTAL
Intervention: Operant treatment alone
Number of subjects: 148
Study 9541083 — intervention group
Group type: COMPARATOR
Intervention: Common individual rehabilitation therapy
Number of subjects: 148
Study 7786689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 266
Study 7786689 — intervention group
Group type: COMPARATOR
Intervention: Intravenous propranolol
Number of subjects: 266
Study 2853934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 50 mg three times daily
Number of subjects: 30
Study 2853934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 100 mg three times daily
Number of subjects: 30
Study 2853934 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg three times daily
Number of subjects: 30
Study 2853934 — intervention group
Group type: COMPARATOR
Intervention: Depot GnRH agonist alone
Number of subjects: 30
Study 29694384 — intervention group
Group type: EXPERIMENTAL
Intervention: Major third
Number of subjects: 15
Study 29694384 — intervention group
Group type: EXPERIMENTAL
Intervention: Fifth
Number of subjects: 15
Study 29694384 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoacoustic experiment
Number of subjects: 15
Study 27196332 — intervention group
Group type: EXPERIMENTAL
Intervention: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF)
Number of subjects: 0
Study 27196332 — intervention group
Group type: COMPARATOR
Intervention: Abacavir/Lamivudine + Dolutegravir (ABC/3TC + DTG)
Number of subjects: 0
Study 25458542 — intervention group
Group type: EXPERIMENTAL
Intervention: AscPEG‐2L (PEG and ascorbic acid 2L)
Number of subjects: 292
Study 25458542 — intervention group
Group type: EXPERIMENTAL
Intervention: PiMg (sodium picosulfate and magnesium citrate 500 mL plus 2L of clear fluids)
Number of subjects: 292
Study 25458542 — intervention group
Group type: COMPARATOR
Intervention: PEG‐ELS 4L (control group)
Number of subjects: 292
Study 23548451 — intervention group
Group type: EXPERIMENTAL
Intervention: soft supportive foam orthotic (FO)
Number of subjects: 30
Study 23548451 — intervention group
Group type: EXPERIMENTAL
Intervention: foam covered rigid self‐supporting plastic orthotic (PO)
Number of subjects: 30
Study 23548451 — intervention group
Group type: COMPARATOR
Intervention: thin, non supportive orthotic (NO)
Number of subjects: 30
Study 21282546 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home symptom monitoring with clinician alerts for severe symptoms
Number of subjects: 100
Study 21282546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alerts)
Number of subjects: 100
Study 19877164 — intervention group
Group type: EXPERIMENTAL
Intervention: AbsPlus intervention
Number of subjects: 54
Study 19877164 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 16396766 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan 1.25 mg/m² on days 1-5 for three 21-day cycles, followed by thalidomide starting at 100 mg/day (escalated to 300 mg/day if tolerated) for up to 1 year.
Number of subjects: 45
Study 16396766 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (100 mg/day, escalated to 300 mg/day if tolerated) for up to 1 year.
Number of subjects: 45
Study 12755459 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment plus contingency management (DT+)
Number of subjects: 127
Study 12755459 — intervention group
Group type: COMPARATOR
Intervention: Day treatment (DT)
Number of subjects: 127
Study 10769525 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 25
Study 10769525 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone sodium
Number of subjects: 25
Study 9191659 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact (Sandoz Nutrition, Minneapolis, Minn), an immune-enhancing diet enhanced with omega-3 fatty acids, arginine, and RNA
Number of subjects: 50
Study 9191659 — intervention group
Group type: COMPARATOR
Intervention: Replete (Clintec, Deerfield, Ill), standard high-protein diet
Number of subjects: 50
Study 2201728 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 48
Study 2201728 — intervention group
Group type: COMPARATOR
Intervention: 0.25 mg triazolam
Number of subjects: 48
Study 7011248 — intervention group
Group type: EXPERIMENTAL
Intervention: des-tyrosine-gamma-endorphin (DT gamma E)
Number of subjects: 10
Study 7011248 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 31765805 — intervention group
Group type: EXPERIMENTAL
Intervention: RV-LV
Number of subjects: 419
Study 31765805 — intervention group
Group type: EXPERIMENTAL
Intervention: QLV
Number of subjects: 419
Study 31765805 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of QLV and RV-LV
Number of subjects: 419
Study 30695733 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback (HRV-BF)
Number of subjects: 0
Study 30695733 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28374511 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 331
Study 28374511 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 331
Study 28374511 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII
Number of subjects: 331
Study 25878305 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction plate
Number of subjects: 59
Study 25878305 — intervention group
Group type: COMPARATOR
Intervention: Elastic stable intramedullary nailing
Number of subjects: 59
Study 23497883 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (SFO)
Number of subjects: 20
Study 23497883 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin olive oil (VOO)
Number of subjects: 20
Study 23497883 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed seed oil with added dimethylpolysiloxane (SOX)
Number of subjects: 20
Study 23497883 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural antioxidants from olives (SOP)
Number of subjects: 20
Study 21679268 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QOL) assessment among treatment seeking MA users
Number of subjects: 838
Study 21679268 — intervention group
Group type: EXPERIMENTAL
Intervention: Employment status
Number of subjects: 838
Study 19365295 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription copayment (copay) policy
Number of subjects: 0
Study 19365295 — intervention group
Group type: EXPERIMENTAL
Intervention: Income-based deductibles plus coinsurance (IBD) policy
Number of subjects: 0
Study 17020440 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined behavioural intervention (CBI)
Number of subjects: 0
Study 17020440 — intervention group
Group type: COMPARATOR
Intervention: CBI and medical management with placebos
Number of subjects: 0
Study 17020440 — intervention group
Group type: COMPARATOR
Intervention: Placebo with medical management
Number of subjects: 0
Study 17020440 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with medical management
Number of subjects: 0
Study 17020440 — intervention group
Group type: EXPERIMENTAL
Intervention: CBI with medical management
Number of subjects: 0
Study 17020440 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with CBI and medical management
Number of subjects: 0
Study 17020440 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall frequency of hospitalisation, emergency treatment, use of medication, detoxification
Number of subjects: 0
Study 15496647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 5 mg/kg
Number of subjects: 112
Study 15496647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 15 mg/kg
Number of subjects: 112
Study 15496647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine doses of 11 to 68 mg/kg/day
Number of subjects: 112
Study 15496647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 112
Study 11214809 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure
Number of subjects: 0
Study 11214809 — intervention group
Group type: EXPERIMENTAL
Intervention: Collateral information
Number of subjects: 0
Study 11214809 — intervention group
Group type: EXPERIMENTAL
Intervention: Doll play
Number of subjects: 0
Study 11214809 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect
Number of subjects: 0
Study 11214809 — intervention group
Group type: COMPARATOR
Intervention: Expert judgments
Number of subjects: 0
Study 11214809 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of sexual abuse literature
Number of subjects: 0
Study 11214809 — intervention group
Group type: COMPARATOR
Intervention: Child-believing attitudes
Number of subjects: 0
Study 9924334 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxymetacaine 0.5%
Number of subjects: 53
Study 9924334 — intervention group
Group type: COMPARATOR
Intervention: Amethocaine 0.5%
Number of subjects: 53
Study 8555557 — intervention group
Group type: EXPERIMENTAL
Intervention: LVAD support
Number of subjects: 8
Study 3214682 — intervention group
Group type: EXPERIMENTAL
Intervention: nandrolone decanoate + calcium
Number of subjects: 0
Study 3214682 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol + norethisterone acetate + calcium
Number of subjects: 0
Study 3214682 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 31923550 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Activated Reliever-Triggered ICS (PARTICS)
Number of subjects: 33
Study 31923550 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 33
Study 29471905 — intervention group
Group type: EXPERIMENTAL
Intervention: Care sought from informal providers
Number of subjects: 1265
Study 29471905 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population with TB symptoms
Number of subjects: 1265
Study 26675536 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound catheter placement plus standard postoperative analgesia
Number of subjects: 92
Study 26675536 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative analgesia alone
Number of subjects: 92
Study 25331922 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient psychodynamic psychotherapy
Number of subjects: 90
Study 25331922 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 90
Study 24330605 — intervention group
Group type: EXPERIMENTAL
Intervention: RP-G28 (galacto-oligosaccharide) administered for 35 days
Number of subjects: 85
Study 24330605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85